Orexo

From Wikipedia, the free encyclopedia
Orexo
TypePublic
Nasdaq Stockholm: ORX
ISINSE0000736415
IndustryPharmaceutical
Founded1995 (1995)
HeadquartersUppsala, Sweden
Area served
Worldwide
Key people
Nikolaj Sørensen
(CEO)
ProductsSee list
RevenueIncrease SEK 429.4 million (2013)[1]
Decrease SEK 154.9 million (2013)[1]
Number of employees
108 (2013) [1]
WebsiteOrexo.com
Footnotes / references
Employee and financial data as of 2014[needs update]

Orexo is a pharmaceutical company based in Uppsala, Sweden initially financed with venture capital provided by HealthCap.

The company was founded in 1995 and their first product Diabact UBT, a breath test for diagnosing the causative agent of stomach ulcers (Helicobacter pylori), was introduced in 2000.[2] In 2003, the company adopted the name Orexo and in 2005 the company was listed on the Stockholm Stock Exchange.[2]On March 29, 2019 a U.S. jury rejected a claim by Sweden’s Orexo AB that two generic opioid-addiction treatments created by Teva Pharmaceutical Industries Ltd. infringed a patent for Orexo’s biggest drug, Zubsolv.[3]

Products[]

  • Abstral, for the treatment of breakthrough cancer pain. It was approved in 2008 in Europe and for marketing in United States by the FDA in 2011.[2]
  • Edluar, for the treatment of short-term insomnia. FDA approved in 2009.[2]
  • Zubsolv a dissolvable tablet which combines the drugs buprenorphine and naloxone and treats opioid dependency and addiction.[4] FDA approved in July 2013.[4] Launched in the United States in September 2013 [5]

References[]

  1. ^ Jump up to: a b c "2013 Annual Report". Orexo. 2014. Retrieved October 12, 2014.
  2. ^ Jump up to: a b c d "History". Orexo. Retrieved July 5, 2013.
  3. ^ "Teva Wins Patent Case Related to Orexo Opioid-Treatment Drug". 2019-03-29. Retrieved 2019-05-21.
  4. ^ Jump up to: a b Toni Clarke (July 4, 2013). "U.S. FDA approves Orexo drug to treat opioid addiction". Reuters. Retrieved July 5, 2013.
  5. ^ Press releases - Orexo

External links[]

Retrieved from ""